Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Genome Med
Autori principali: Chalmers, Zachary R., Connelly, Caitlin F., Fabrizio, David, Gay, Laurie, Ali, Siraj M., Ennis, Riley, Schrock, Alexa, Campbell, Brittany, Shlien, Adam, Chmielecki, Juliann, Huang, Franklin, He, Yuting, Sun, James, Tabori, Uri, Kennedy, Mark, Lieber, Daniel S., Roels, Steven, White, Jared, Otto, Geoffrey A., Ross, Jeffrey S., Garraway, Levi, Miller, Vincent A., Stephens, Phillip J., Frampton, Garrett M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395719/
https://ncbi.nlm.nih.gov/pubmed/28420421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-017-0424-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi